What The White House Is NOT Telling You About The "Green Revolution."
Governments across the globe want to go "All Electric" by 2035. There's one rare metal that could cripple these plans. Without it, going green is impossible. And that's why there's a modern-day gold-rush for this rare metal.
Read The Full Story On This "Gold Rush"

IMM Insider Trading (ImmuPharma)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £10,000
Insider Selling (Last 12 Months): GBX 0

ImmuPharma Insider Trading History Chart

This chart shows the insider buying and selling history at ImmuPharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ImmuPharma Share Price & Price History

Current Price: GBX 7.36
Price Change: Price Decrease of -0.14 (-1.87%)
As of 10/19/2021 01:00 AM ET

This chart shows the closing price history over time for IMM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
What The White House Is NOT Telling You About The "Green Revolution."
Governments across the globe want to go "All Electric" by 2035. There's one rare metal that could cripple these plans. Without it, going green is impossible. And that's why there's a modern-day gold-rush for this rare metal.
Read The Full Story On This "Gold Rush"

ImmuPharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/24/2021Sanjeev PandyaInsiderBuy125,000GBX 8£10,000
See Full Table
Insider Selling at ImmuPharma?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for ImmuPharma and related companies.

SEC Filings (Institutional Ownership Changes) for ImmuPharma (LON:IMM)

ImmuPharma logo
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity, metabolism, anti-infectives, and cancer. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology; and BioGlucagon a therapy for low sugar events in diabetes. ImmuPharma plc has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Read More on ImmuPharma

Today's Range

Now: GBX 7.36
Low: 7
High: 7.70

50 Day Range

MA: GBX 7.73
Low: 7.04
High: 9.40

52 Week Range

Now: GBX 7.36
Low: 6.89
High: 14.75

Volume

263,377 shs

Average Volume

962,136 shs

Market Capitalization

£18.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of ImmuPharma?

ImmuPharma's top insider shareholders include:
  1. Sanjeev Pandya (Insider)
What The White House Is NOT Telling You About The "Green Revolution."
Governments across the globe want to go "All Electric" by 2035. There's one rare metal that could cripple these plans. Without it, going green is impossible. And that's why there's a modern-day gold-rush for this rare metal.
Read The Full Story On This "Gold Rush"